Analysts expect Opiant Pharmaceuticals Inc (NASDAQ:OPNT) to announce earnings per share (EPS) of $0.35 for the current quarter, Zacks reports. Two analysts have issued estimates for Opiant Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.10 and the highest estimate coming in at $0.60. Opiant Pharmaceuticals reported earnings of ($0.37) per share during the same quarter last year, which suggests a positive year over year growth rate of 194.6%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 19th.
On average, analysts expect that Opiant Pharmaceuticals will report full-year earnings of $2.47 per share for the current financial year, with EPS estimates ranging from $2.05 to $3.14. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.29) per share, with EPS estimates ranging from ($2.65) to $3.21. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Opiant Pharmaceuticals.
Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Tuesday, November 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.10 by $1.87. The firm had revenue of $20.64 million for the quarter, compared to analyst estimates of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%.
Separately, Northland Securities reaffirmed a “buy” rating and issued a $42.00 price target on shares of Opiant Pharmaceuticals in a research note on Thursday, November 7th.
In other news, Director Ann L. Macdougall purchased 5,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $13.51 per share, with a total value of $67,550.00. Also, insider Phil Skolnick sold 7,143 shares of Opiant Pharmaceuticals stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $13.47, for a total value of $96,216.21. Insiders bought 7,885 shares of company stock worth $106,604 over the last ninety days. Corporate insiders own 30.88% of the company’s stock.
A number of institutional investors have recently made changes to their positions in OPNT. BlackRock Inc. lifted its position in Opiant Pharmaceuticals by 93.5% during the second quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock worth $276,000 after buying an additional 10,045 shares in the last quarter. Morgan Stanley lifted its position in Opiant Pharmaceuticals by 1,000.3% during the second quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock worth $297,000 after buying an additional 20,377 shares in the last quarter. Wedge Capital Management L L P NC purchased a new position in Opiant Pharmaceuticals during the third quarter worth approximately $363,000. Finally, Stonepine Capital Management LLC lifted its position in Opiant Pharmaceuticals by 7.0% during the second quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock worth $4,180,000 after buying an additional 20,574 shares in the last quarter. Hedge funds and other institutional investors own 21.49% of the company’s stock.
Shares of NASDAQ:OPNT traded up $0.07 during trading on Friday, reaching $13.43. The stock had a trading volume of 6,349 shares, compared to its average volume of 12,766. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.28 and a current ratio of 4.28. The business has a fifty day moving average price of $14.10 and a 200-day moving average price of $14.21. The stock has a market cap of $54.71 million, a PE ratio of 9.14 and a beta of 0.23. Opiant Pharmaceuticals has a 1-year low of $9.98 and a 1-year high of $18.23.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
See Also: Analyst Ratings Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.